Alejandro Andrés Gracia

Dr. Alejandro Andrés Gracia

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
AGAlejandro Andrés Gracia
Alejandro Andrés Gracia
LTLeticia Tardín
Leticia Tardín
PRPaula Razola
Paula Razola
ASAlbert Santapau
Albert Santapau
EPEnrique Prats
Enrique Prats
JBJavier Banzo
Javier Banzo
A 57-year-old woman with infiltrating ductal carcinoma of the right breast underwent lymph node scintigraphy with Tc-99m-nanocolloid for preoperative sentinel node localization. On planar images, an unusual pattern of lymphatic drainage was observed. We performed a chest SPECT/CT, revealing an interpectoral sentinel node, ie, Rotter's node. The patient underwent radioguided surgery and the sentinel node was located intraoperatively, and found to be disease-free. SPECT/CT fusion techniques have enhanced precision in locating sentinel nodes, enabling the surgeon to shorten surgical times.

30 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SRSara Elena Campos Ramírez
Sara Elena Campos Ramírez
AGAlejandro Andrés Gracia
Alejandro Andrés Gracia
CACarmen Blanco Abad
Carmen Blanco Abad
PPPaula Gomila Pons
Paula Gomila Pons
PMPablo Gómez Mugarza
Pablo Gómez Mugarza
VAVicente Alonso-Orduña
Vicente Alonso-Orduña
Background: Therapy using lutetium-177 dotatate (177LU) was approved in Europe for the treatment of advanced neuroendocrine tumors (NETs) in 2017. Since then, it has become part of the strategies in the treatment of NETs, making it now possible to evaluate real-life results. Research Design and Methods: Single-arm, retrospective, multicenter, cohort study of all the patients with metastatic NETs treated with 177LU (four cycles of 200 mCi every 8 weeks) in the two medical centers dedicated to the treatment of NETs from the region of Aragón, Spain, from 2017 to 2024. Descriptive analysis of demographic characteristics, efficacy, and survival analysis were performed using the statistics software Jamovi 2.6.14. Results: Sixty-eight patients were included. The majority were male, and the most frequent primary location was the pancreas. The ORR was 30.9%. The DCR was 88%. The median OS was 47.4 months [95% CI, 25.6–NE]. The median PFS was 26.1 months [95% CI, 18.5–68.3]. High-grade tumors, multiple previous treatments, and pancreatic location presented worse OS. In total, 42.6% presented any grade adverse event (17.2% hematologic, 30.9% GI symptoms). Conclusions: The efficacy of 177LU in our study is like that observed in similar studies. Acceptable tolerance has been shown. Pancreatic tumors, previous treatments, and higher grades demonstrated worse outcomes. The new research line must consider the use of treatment with 177LU in earlier lines for metastatic disease as well as its possible use in local or locally advanced disease.

6 January 2020 in Amyloid
Verified
Journal Article
Closed access
ABAna Roteta Unceta Barrenechea
Ana Roteta Unceta Barrenechea
MAMiguel Ángel Aibar Arregui
Miguel Ángel Aibar Arregui
AGAlejandro Andrés Gracia
Alejandro Andrés Gracia
JPJorge Melero Polo
Jorge Melero Polo
CPCarmen Lahuerta Pueyo
Carmen Lahuerta Pueyo
MCMiguel Ángel Torralba Cabeza
Miguel Ángel Torralba Cabeza
(2020). Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin: a comment. Amyloid. Ahead of Print.

15 January 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
OMOctavio Jiménez Melo
Octavio Jiménez Melo
MLMaría Jesús Pinilla Lozano
María Jesús Pinilla Lozano
ERElena Morte Romea
Elena Morte Romea
AGAlejandro Andrés Gracia
Alejandro Andrés Gracia
A 76-year-old woman presented in cardiology clinic with New York Heart Association class II dyspnoea for the last 4 months. She had a history of severe mitral and moderate aortic stenosis that required double mechanical valve replacement 15 years ago. B-type natriuretic peptide was normal, and transthoracic echocardiogram showed that both prostheses had similar gradients to the last ones measured. Pulmonary function tests were normal. The patient kept referring persistent dyspnoea and other non-specific symptoms. Physical examination revealed significant aortic and mitral systolic murmurs. Erythematous painless macules on the palms and dark red subungual lesions in the nail beds of the fourth finger were found on both hands ( Figure 1). Routine blood cultures detected growth of Streptococcus gordonii. Although initial transthoracic echocardiogram could not detect any vegetation, a transoesophageal echocardiogram was performed and showed two mobile images in the atrial side of the mitral ring of 7 mm in length, suggesting vegetation, causing a mild periprosthetic leak in the mitral–aortic junction. F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/computed tomography (CT) was performed due to the limitation of echocardiogram, and revealed two foci of hypermetabolism, in the aortic and predominantly the mitral valve ( Figure 2). According to modified Duke Criteria, patient was diagnosed of definite infective endocarditis fulfilling two major (positive echocardiography, abnormal activity around the site of prosthetic valve implantation by 18F-FDG PET/CT) and three minor criteria (predisposing heart condition, vascular phenomena—Janeway lesions—and positive blood culture). The case was discussed in a multidisciplinary heart team and a conservative medical approach based on ceftriaxone was decided. Janeway lesions are irregular, painless, erythematous or haemorrhagic macules, or papules commonly found on the palms and soles. The pathogenesis of Janeway lesions is still a controversial topic in the literature, but the main hypothesis is based on septic embolic events. Although current diagnosis of endocarditis is unlikely to be made only on the basis of Janeway lesions, the use of classic cutaneous signs of this entity could not be forgotten by clinicians, even in the post-antibiotic era of the developed world, to achieve the correct diagnosis.

9 April 2024 in Otolaryngologia Polska
Verified
Journal Article
Closed access
FGFernando Garcia-Curdi
Fernando Garcia-Curdi
YLYolanda Lois-Ortega
Yolanda Lois-Ortega
Ana MuniesaAna Muniesa
Ana Muniesa
AGAlejandro Andrés Gracia
Alejandro Andrés Gracia
JSJosé Miguel Sebastián-Cortés
José Miguel Sebastián-Cortés
JLJulio José Lambea-Sorrosal
Julio José Lambea-Sorrosal
Introduction: Although PET/CT is effective for staging HNSCC, its impact on patient management is somewhat controversial. For this reason, we considered it necessary to carry out a study in order to verify whether PET/CT helps to improve the prognosis and treatment in patients. This study was designed to address the impact of PET-FDG imaging when used alongside CT in the staging and therapeutic management of patients with HNSCC. Material and methods: Data was collected from 169 patients diagnosed with HNSCC with both CT and PET/CT (performed within a maximum of 30 days of each other). It was evaluated whether discrepancies in the diagnosis of the two imaging tests had impacted the treatment. Results: The combined use of CT and PET/CT led to a change in the treatment of 67 patients, who represented 39.7% of the sample. In 27.2% of cases, it entailed a change in the type of treatment which the patient received. In 3.0% of the cases, using both diagnostic tests led to modifications of the therapeutic intention of our patients. Conclusions: Using PET/CT in addition to the conventional imaging method in staging resulted in more successful staging and more appropriate therapeutic decision-making.